Cognition Therapeutics, Inc. Amortization of Debt Discount (Premium)
Cognition Therapeutics, Inc. (CGTX) reported Amortization of Debt Discount (Premium) of $352.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2023-03-23
- Cognition Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Cognition Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Cognition Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2021-06-30 was $92.00K.
- Cognition Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2021-03-31 was $260.00K.
- Cognition Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2021 was $352.00K, a 54.99% decline from fiscal 2020.
- Cognition Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2020 was $782.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $92.00K derived: sum of 3 quarters · filed 2023-03-23 | $352.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $92.00K derived: sum of 2 quarters · filed 2022-11-14 | $352.00K 10-Q · filed 2022-11-14 | $598.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $92.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $352.00K 10-Q · filed 2022-08-09 | $598.00K derived: sum of 3 quarters · filed 2022-08-09 | $826.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $260.00K 10-Q · filed 2022-05-11 | $506.00K derived: sum of 2 quarters · filed 2022-05-11 | $734.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $246.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $474.00K derived: sum of 2 quarters · filed 2022-03-30 | $782.00K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $228.00K 10-Q · filed 2021-11-17 | $536.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |